Curis to Present at SVB Leerink 10th Annual Global Healthcare Conference

Rhea-AI Summary

Curis, a biotechnology firm specializing in cancer therapeutics, announced that CEO James Dentzer will present at the SVB Leerink 10th Annual Global Healthcare Conference on February 26, 2021, at 1:40 PM ET. A live webcast of the presentation will be accessible on Curis' website, with a replay available for 90 days. Curis is known for its innovative collaborations in immuno-oncology, including exclusive licenses for several small molecule antagonists and kinase inhibitors currently in clinical trials. For further details, visit www.curis.com.

LEXINGTON, Mass., Feb. 19, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the SVB Leerink 10^th Annual Global Healthcare Conference on Friday, February 26^th, 2021 at 1:40 pm ET.

A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.

About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/curis-to-present-at-svb-leerink-10th-annual-global-healthcare-conference-301231523.html

SOURCE Curis, Inc.

FAQ

When will Curis present at the SVB Leerink Global Healthcare Conference?

Curis will present on February 26, 2021, at 1:40 PM ET.

Who is presenting for Curis at the healthcare conference?

James Dentzer, the President and CEO of Curis, will present.

How can I watch the Curis presentation at the conference?

A live webcast will be available on Curis' website under the 'Events & Presentations' section.

What products is Curis developing in cancer treatment?

Curis is developing several therapeutics, including CA-170, CA-327, and CA-4948, currently in clinical trials.

Where can I find more information about Curis?

More information can be found on their website at www.curis.com.